Nurix Therapeutics Inc logo

NRIX

Nurix Therapeutics Inc

$15.48

Earnings Summary

Revenue
$11.43Mn
Net Profits
$-45.4Mn
Net Profit Margins
-397.14%

Highlights

Revenue:

Nurix Therapeutics Inc’s revenue jumped 61.22% since last year same period to $11.43Mn in the Q2 2022. On a quarterly growth basis, Nurix Therapeutics Inc has generated 18.82% jump in its revenue since last 3-months.

Net Profits:

Nurix Therapeutics Inc’s net profit fell -72.09% since last year same period to $-45.4Mn in the Q2 2022. On a quarterly growth basis, Nurix Therapeutics Inc has generated -6.74% fall in its net profits since last 3-months.

Net Profit Margins:

Nurix Therapeutics Inc’s net profit margin fell -6.74% since last year same period to -397.14% in the Q2 2022. On a quarterly growth basis, Nurix Therapeutics Inc has generated 10.17% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Nurix Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.98
EPS Estimate Current Year
-0.98

Highlights

EPS Estimate Current Quarter:

Nurix Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.98 - a 1.01% jump from last quarter’s estimates.

EPS Estimate Current Year:

Nurix Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.98.

Key Ratios

Key ratios of the Nurix Therapeutics Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-1.01

Highlights

Earning Per Share (EPS):

Nurix Therapeutics Inc’s earning per share (EPS) fell -68.33% since last year same period to -1.01 in the Q2 2022. This indicates that the Nurix Therapeutics Inc has generated -68.33% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-04-08
-0.88
-0.95
-7.95%
2022-07-07
-0.99
-1.01
-2.02%

Company Information

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.

Organisation
Nurix Therapeutics Inc
Employees
2.02K
Industry
Health Technology